Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Receivables - Accured (2022 - 2025)

Perspective Therapeutics' Revenue - Other history spans 4 years, with the latest figure at $234000.0 for Q4 2024.

  • For Q4 2024, Receivables - Accured changed N/A year-over-year to $880000.0; the TTM value through Dec 2024 reached $880000.0, changed N/A, while the annual FY2024 figure was $880000.0, N/A changed from the prior year.
  • Revenue - Other for Q4 2024 was $234000.0 at Perspective Therapeutics, down from $369000.0 in the prior quarter.
  • Across five years, Revenue - Other topped out at $588000.0 in Q2 2023 and bottomed at $233000.0 in Q1 2023.